Ovarian cancer epidemiology in the era of collaborative team science

Cancer Causes and Control

Volumn 28, Issue 5, 2017, Pages 487-495

  Cannioto, Rikki A ^a   Trabert, Britton ^b   Poole, Elizabeth M ^c   Schildkraut, Joellen M ^d  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Consortium; Epidemiology; Ovarian cancer

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR; TUMOR MARKER;

ACCESS TO INFORMATION; ALLELE; ARTICLE; BODY MASS; BODY SIZE; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DISEASE MARKER; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; ETHNIC DIFFERENCE; FAMILY HISTORY; FEMALE; FOLLOW UP; GENETIC SUSCEPTIBILITY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEALTH CARE ORGANIZATION; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; INFORMATION PROCESSING; INTERSECTORAL COLLABORATION; LIFESTYLE; MENOPAUSE; OBESITY; ONCOGENE; ORAL CONTRACEPTIVE USE; OUTCOME ASSESSMENT; OVARY CARCINOMA; PHYSICAL ACTIVITY; PREDICTION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RISK FACTOR; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TISSUE MICROARRAY; COOPERATION; METHODOLOGY; OVARIAN NEOPLASMS;

CASE-CONTROL STUDIES; COOPERATIVE BEHAVIOR; FEMALE; HUMANS; OVARIAN NEOPLASMS; RESEARCH DESIGN; RISK FACTORS;

EID: 85014747277     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-017-0862-6     Document Type: Article

References (44)

1. Burgio MR, Ioannidis JP, Kaminski BM, Derycke E, Rogers S, Khoury MJ, Seminara D (2013) Collaborative cancer epidemiology in the 21st century: the model of cancer consortia. Cancer Epidemiol Biomark Prev 22(12):2148–2160
2. Hoover RN (2007) The evolution of epidemiologic research: from cottage industry to “big” science. Epidemiology 18(1):13–17
3. The National Cancer Institute’s Epidemiology and Genomics Research Program-supported cancer epidemiology consortia. http://epi.grants.cancer.gov/Consortia/#def. Accessed 15 Aug 2016
4. Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K (2016) Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med 20(4):581–593
5. Blagden SP (2015) Harnessing pandemonium: the clinical implications of tumor heterogeneity in ovarian cancer. Front Oncol 5:149
6. Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok SC, Bandera CA (2005) Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet 161(2):170–173
7. Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO et al (2016) Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J Clin Oncol 34(24):2888–2898
8. Berchuck A, Schildkraut JM, Pearce CL, Chenevix-Trench G, Pharoah PD (2008) Role of genetic polymorphisms in ovarian cancer susceptibility: development of an International Ovarian Cancer Association Consortium. Adv Exp Med Biol 622:53–67
9. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG et al (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies. Lancet Oncol 13(4):385–394
10. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH, Australian Cancer S et al (2013) Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer 20(2):251–262
11. Faber MT, Kjaer SK, Dehlendorff C, Chang-Claude J, Andersen KK, Hogdall E, Webb PM, Jordan SJ, Rossing MA, Doherty JA et al (2013) Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies. Cancer Causes Control 24(5):989–1004
12. Kelemen LE, Bandera EV, Terry KL, Rossing MA, Brinton LA, Doherty JA, Ness RB, Kjaer SK, Chang-Claude J, Kobel M et al (2013) Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. BMC Cancer 13:28
13. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, Risch H, Wu AH, Webb PM, Moysich K et al (2013) Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case–control studies. Int J Epidemiol 42(2):579–589
14. Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, Lurie G, Thompson PJ, Carney ME, Weber RP, Akushevich L, Lo-Ciganic WH et al (2013) Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls. Cancer Prevent Res (Philadelphia) 6(8):811–821
15. Trabert B, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ et al (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 106(2):djt431
16. Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE, Fasching PA et al (2015) Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer 113(5):817–826
17. Cannioto R, LaMonte MJ, Risch HA, Hong CC, Sucheston-Campbell LE, Eng KH, Szender JB, Chang-Claude J, Schmalfeldt B, Klapdor R et al (2016) Chronic recreational physical inactivity and epithelial ovarian cancer risk: evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomark Prev 25:1124
18. Cannioto RA, LaMonte MJ, Kelemen LE, Risch HA, Eng KH, Minlikeeva AN, Hong CC, Szender JB, Sucheston-Campbell L, Joseph JM et al (2016) Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. Br J Cancer 115(1):95–101
19. Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J, Doherty JA, Menon U, Cramer DW, Gayther SA et al (2016) Association between menopausal estrogen-only therapy and ovarian carcinoma risk. Obstet Gynecol 127(5):828–836
20. Kobel M, Kalloger SE, Lee S, Duggan MA, Kelemen LE, Prentice L, Kalli KR, Fridley BL, Visscher DW, Keeney GL et al (2013) Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomark Prev 22(10):1677–1686
21. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Hogdall E, Deen S, Wentzensen N, Moysich KB et al (2013) Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 14(9):853–862
22. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet (London. England) 385(9980):1835–1842
23. Collaborative Group on Epidemiological Studies of Ovarian C (2012) Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 9(4):e1001200.
24. Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet (London, England) 371(9609):303–314.
25. Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2012) Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol 13(9):946–956
26. Schildkraut JM, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Funkhouser E, Peters E, Schwartz AG, Terry P et al (2014) A multi-center population-based case–control study of ovarian cancer in African–American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer 14:688
27. Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C (1999) Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28(1):1–9
28. Boffetta P, Armstrong B, Linet M, Kasten C, Cozen W, Hartge P (2007) Consortia in cancer epidemiology: lessons from InterLymph. Cancer Epidemiol Biomark Prev 16(2):197–199
29. Clyde MA, Palmieri Weber R, Iversen ES, Poole EM, Doherty JA, Goodman MT, Ness RB, Risch HA, Rossing MA, Terry KL et al (2016) Risk prediction for epithelial ovarian cancer in 11 United States-based case–control studies: incorporation of epidemiologic risk factors and 17 confirmed genetic loci. Am J Epidemiol 184:555–569
30. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY et al (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 42(10):880–884
31. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK et al (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42(10):874–879
32. Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley J, Chen X, Spindler TJ et al (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet 47(8):888–897
33. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H et al (2013) GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 362–370(4):370e361–370e362
34. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R et al (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41(9):996–1000
35. Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ, Li Q, Marks JR, Berchuck A, Lee JM et al (2015) Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis 36(11):1341–1353
36. Phelan CM KK, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan M, Chornokur G, Earp MA, Lyra PA, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D et al (2017) Identification of twelve novel susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet (in press)
37. Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet (London, England) 371(9609):303–314
38. Fortier I, Doiron D, Burton P, Raina P (2011) Invited commentary: consolidating data harmonization—how to obtain quality and applicability? Am J Epidemiol 174(3):261–264 (author reply 265–266)
39. Stukel TA, Demidenko E, Dykes J, Karagas MR (2001) Two-stage methods for the analysis of pooled data. Stat Med 20(14):2115–2130
40. Friedenreich CM (2002) Commentary: improving pooled analyses in epidemiology. Int J Epidemiol 31(1):86–87
41. Preston-Martin S, Pogoda JM, Schlehofer B, Blettner M, Howe GR, Ryan P, Menegoz F, Giles GG, Rodvall Y, Choi NW et al (1998) An international case–control study of adult glioma and meningioma: the role of head trauma. Int J Epidemiol 27(4):579–586
42. Morton LM, Sampson JN, Cerhan JR, Turner JJ, Vajdic CM, Wang SS, Smedby KE, de Sanjose S, Monnereau A, Benavente Y et al (2014) Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr 2014(48):1–14
43. Boyle P (1990) SEARCH programme of the International Agency of Research on Cancer. Eur J Cancer (Oxford, England) 26(5):547–549
44. Riboli E, Kaaks R (1997) The EPIC project: rationale and study design. European prospective investigation into cancer and nutrition. Int J Epidemiol 26(Suppl 1):S6–S14